You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlbendazole
Accession NumberDB00518  (APRD00782)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Structure
Thumb
Synonyms
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-(Propylthio)-2-carbomethoxyaminobenzimidazole
Albendazol
Albendazol
Albendazole
Albendazolum
Albenza
Eskazole
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
Proftril
Ricobendazole
Rycobendazole
Valbazen
Zentel
External Identifiers
  • RS-8852
  • SKF 62979
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Albenzatablet, film coated200 mg/1oralAmedra Pharmaceuticals LLC1996-06-11Not applicableUs
Albenzatablet, film coated200 mg/1oralRx Pak Division Of Mc Kesson Corporation1996-06-11Not applicableUs
Albenzatablet, film coated200 mg/1oralDepartment Of State Health Services, Pharmacy Branch1996-06-11Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbentelAristopharma
ABZIndoco
AcurePharmix
AdazolRoemmers
ALRadicura
BandVensat
BandyMankind
BazoleNeutro Pharma
Ben-AAcme
BenrodInvision
BentilAlliance
BenzolMercury Lab
BenzoleFlamingo Pharmacueticals
BevindazolVincenti
BiwomZydus
BruzolBruluart
BuxolBuffington's
CentalBrisafarma
ChampsCCM
CicloparWeider
CidazoleJuggat
ClearwormInvision
DalbenKrka
DesparIcofarma
EskazoleGlaxoSmithKline
ZentelGlaxoSmithKline
ZolbenSanofi-Aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIF4216019LN
CAS number54965-21-8
WeightAverage: 265.331
Monoisotopic: 265.088497429
Chemical FormulaC12H15N3O2S
InChI KeyInChIKey=HXHWSAZORRCQMX-UHFFFAOYSA-N
InChI
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
IUPAC Name
methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate
SMILES
CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Alkylarylthioether
  • Benzenoid
  • Aminoimidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
PharmacodynamicsAlbendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.
Mechanism of actionAlbendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
Related Articles
AbsorptionPoorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g)
Volume of distributionNot Available
Protein binding70% bound to plasma protein
Metabolism

Hepatic. Rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine.

SubstrateEnzymesProduct
Albendazole
Not Available
albendazole sulfoneDetails
Albendazole
Not Available
albendazole sulfoxideDetails
Route of eliminationAlbendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.
Half lifeTerminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).
ClearanceNot Available
ToxicitySymptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.
Affected organisms
  • Helminthic Microorganisms
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.9381
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6637
P-glycoprotein inhibitor INon-inhibitor0.6928
P-glycoprotein inhibitor IINon-inhibitor0.6089
Renal organic cation transporterNon-inhibitor0.8433
CYP450 2C9 substrateNon-substrate0.7742
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6147
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8347
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8037
Ames testNon AMES toxic0.7894
CarcinogenicityNon-carcinogens0.9334
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0752 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9707
hERG inhibition (predictor II)Non-inhibitor0.8549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedoral200 mg/1
Prices
Unit descriptionCostUnit
Albenza 200 mg tablet1.91USD tablet
Albendazole powder0.41USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point208-210Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to Smith Kline Corp.
water solubilityPractically insolubleNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0228 mg/mLALOGPS
logP3.22ALOGPS
logP3.2ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)9.51ChemAxon
pKa (Strongest Basic)4.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.01 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.01 m3·mol-1ChemAxon
Polarizability29.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to
Smith Kline Corp.

US3915986
General References
  1. Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6. [PubMed:17350811 ]
  2. Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20. [PubMed:11110097 ]
  3. Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. [PubMed:11343808 ]
  4. Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7. [PubMed:8228321 ]
External Links
ATC CodesP02CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.4 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Albendazole can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Albendazole.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Albendazole.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Albendazole.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Albendazole.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Albendazole.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Albendazole.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Albendazole.
AmiodaroneThe metabolism of Albendazole can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Albendazole.
AmodiaquineThe serum concentration of Albendazole can be decreased when it is combined with Amodiaquine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Albendazole.
AprepitantThe serum concentration of Albendazole can be increased when it is combined with Aprepitant.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Albendazole.
AtazanavirThe metabolism of Albendazole can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Albendazole.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Albendazole.
AtomoxetineThe metabolism of Albendazole can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Albendazole.
AzithromycinThe metabolism of Albendazole can be decreased when combined with Azithromycin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Albendazole.
BevacizumabBevacizumab may increase the cardiotoxic activities of Albendazole.
BexaroteneThe serum concentration of Albendazole can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Albendazole can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Albendazole.
BortezomibThe metabolism of Albendazole can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Albendazole can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Albendazole.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Albendazole.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Albendazole.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Albendazole.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Albendazole.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Albendazole.
CaffeineThe metabolism of Albendazole can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Albendazole.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Albendazole.
CarbamazepineThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Carbamazepine resulting in a loss in efficacy.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Albendazole.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Albendazole.
CeritinibThe serum concentration of Albendazole can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Albendazole.
ChloroquineThe serum concentration of Albendazole can be decreased when it is combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Albendazole.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Albendazole.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Albendazole.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Albendazole.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Albendazole.
CitalopramThe metabolism of Albendazole can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Albendazole can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Albendazole.
ClemastineThe metabolism of Albendazole can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Albendazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Albendazole.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Albendazole.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Albendazole.
ClotrimazoleThe metabolism of Albendazole can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Albendazole.
CobicistatThe metabolism of Albendazole can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Albendazole.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Albendazole.
ConivaptanThe serum concentration of Albendazole can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Albendazole.
CrizotinibThe metabolism of Albendazole can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Albendazole.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Albendazole.
CyclosporineThe metabolism of Albendazole can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Albendazole.
Cyproterone acetateThe serum concentration of Albendazole can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Albendazole.
DabrafenibThe serum concentration of Albendazole can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Albendazole.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Albendazole.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Albendazole.
DarunavirThe metabolism of Albendazole can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Albendazole can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Albendazole.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Albendazole.
DeferasiroxThe serum concentration of Albendazole can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Albendazole can be decreased when combined with Delavirdine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Albendazole.
DexamethasoneThe serum concentration of Albendazole can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Albendazole.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Albendazole.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Albendazole.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Albendazole.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Albendazole.
DigoxinDigoxin may decrease the cardiotoxic activities of Albendazole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Albendazole.
DihydroergotamineThe metabolism of Albendazole can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Albendazole.
DiltiazemThe metabolism of Albendazole can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Albendazole.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Albendazole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Albendazole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Albendazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Albendazole.
DoxycyclineThe metabolism of Albendazole can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Albendazole can be decreased when combined with Dronedarone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Albendazole.
EfavirenzThe serum concentration of Albendazole can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Albendazole.
EnzalutamideThe serum concentration of Albendazole can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Albendazole.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Albendazole.
ErythromycinThe metabolism of Albendazole can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Albendazole.
Eslicarbazepine acetateThe serum concentration of Albendazole can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Albendazole.
EstriolThe serum concentration of Estriol can be increased when it is combined with Albendazole.
EstroneThe serum concentration of Estrone can be increased when it is combined with Albendazole.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Albendazole.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Albendazole.
EtravirineThe serum concentration of Albendazole can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Albendazole.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Albendazole.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Albendazole.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Albendazole.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Albendazole.
FluconazoleThe metabolism of Albendazole can be decreased when combined with Fluconazole.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Albendazole.
FluvoxamineThe metabolism of Albendazole can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Albendazole can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Albendazole can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Albendazole can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Albendazole can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Albendazole.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Albendazole.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Albendazole.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Albendazole.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Albendazole.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Albendazole.
HydroxychloroquineThe serum concentration of Albendazole can be decreased when it is combined with Hydroxychloroquine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Albendazole.
IdelalisibThe serum concentration of Albendazole can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Albendazole can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Albendazole.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Albendazole.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Albendazole.
IndinavirThe metabolism of Albendazole can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Albendazole.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Albendazole.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Albendazole.
IsavuconazoniumThe metabolism of Albendazole can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Albendazole can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Albendazole can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Albendazole can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Albendazole.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Albendazole.
KetoconazoleThe metabolism of Albendazole can be decreased when combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Albendazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Albendazole.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Albendazole.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Albendazole.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Albendazole.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Albendazole.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Albendazole.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Albendazole.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Albendazole.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Albendazole.
LidocaineThe metabolism of Albendazole can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Albendazole.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Albendazole.
LopinavirThe metabolism of Albendazole can be decreased when combined with Lopinavir.
LosartanThe serum concentration of Losartan can be increased when it is combined with Albendazole.
LovastatinThe metabolism of Albendazole can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Albendazole can be increased when it is combined with Luliconazole.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Albendazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Albendazole.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Albendazole.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Albendazole.
MexiletineThe metabolism of Albendazole can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Albendazole.
MifepristoneThe metabolism of Albendazole can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Albendazole.
MitotaneThe serum concentration of Albendazole can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Albendazole.
ModafinilThe serum concentration of Albendazole can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Albendazole.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Albendazole.
NadololThe serum concentration of Nadolol can be increased when it is combined with Albendazole.
NafcillinThe serum concentration of Albendazole can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Albendazole.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Albendazole.
NefazodoneThe metabolism of Albendazole can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Albendazole can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Albendazole.
NetupitantThe serum concentration of Albendazole can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Albendazole can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Albendazole.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Albendazole.
NilotinibThe metabolism of Albendazole can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Albendazole.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Albendazole.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Albendazole.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Albendazole.
OlaparibThe metabolism of Albendazole can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Albendazole.
OsimertinibThe serum concentration of Albendazole can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Albendazole.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Albendazole.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Albendazole.
PalbociclibThe serum concentration of Albendazole can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Albendazole.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Albendazole.
Peginterferon alfa-2bThe serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Albendazole can be increased when combined with Pentobarbital.
PhenobarbitalThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenobarbital resulting in a loss in efficacy.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Albendazole.
PhenytoinThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenytoin resulting in a loss in efficacy.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Albendazole.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Albendazole.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Albendazole.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Albendazole.
PosaconazoleThe metabolism of Albendazole can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Albendazole.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Albendazole.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Albendazole.
PrimaquineThe serum concentration of Albendazole can be decreased when it is combined with Primaquine.
PrimidoneThe metabolism of Albendazole can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Albendazole.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Albendazole.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Albendazole.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Albendazole.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Albendazole.
QuinineThe serum concentration of Quinine can be increased when it is combined with Albendazole.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Albendazole.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Albendazole.
RanolazineThe metabolism of Albendazole can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Albendazole.
RifabutinThe metabolism of Albendazole can be increased when combined with Rifabutin.
RifampicinThe metabolism of Albendazole can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Albendazole.
RifapentineThe metabolism of Albendazole can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Albendazole.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Albendazole.
RitonavirThe metabolism of Albendazole can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Albendazole.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Albendazole.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Albendazole.
RopiniroleThe metabolism of Albendazole can be decreased when combined with Ropinirole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Albendazole.
SaquinavirThe metabolism of Albendazole can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Albendazole.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Albendazole.
SildenafilThe metabolism of Albendazole can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Albendazole.
SiltuximabThe serum concentration of Albendazole can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Albendazole can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Albendazole.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Albendazole.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Albendazole.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Albendazole.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Albendazole.
St. John's WortThe serum concentration of Albendazole can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Albendazole can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Albendazole can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Albendazole.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Albendazole.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Albendazole.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Albendazole.
TelaprevirThe metabolism of Albendazole can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Albendazole.
TelithromycinThe metabolism of Albendazole can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Albendazole.
TenofovirThe metabolism of Albendazole can be decreased when combined with Tenofovir.
TeriflunomideThe serum concentration of Albendazole can be decreased when it is combined with Teriflunomide.
TheophyllineThe metabolism of Albendazole can be decreased when combined with Theophylline.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Albendazole.
TiclopidineThe metabolism of Albendazole can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Albendazole.
TocilizumabThe serum concentration of Albendazole can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Albendazole.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Albendazole.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Albendazole.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Albendazole.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Albendazole.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Albendazole.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Albendazole.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Albendazole.
VemurafenibThe serum concentration of Albendazole can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Albendazole can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Albendazole.
VerapamilThe metabolism of Albendazole can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Albendazole.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Albendazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Albendazole.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Albendazole.
VoriconazoleThe metabolism of Albendazole can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Albendazole.
ZiprasidoneThe metabolism of Albendazole can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Pig roundworm
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
Not Available
Uniprot ID:
F1L7U3
Molecular Weight:
51336.46 Da
References
  1. Solana HD, Sallovitz JM, Lanusse CE, Rodriguez JA: Enantioselective binding of albendazole sulphoxide to cytosolic proteins from helminth parasites. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):7-13. [PubMed:11980387 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Structural molecule activity
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA1A
Uniprot ID:
Q71U36
Molecular Weight:
50135.25 Da
References
  1. Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. [PubMed:11343808 ]
  2. Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6. [PubMed:19846910 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Unfolded protein binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB4B
Uniprot ID:
P68371
Molecular Weight:
49830.72 Da
References
  1. Solana HD, Sallovitz JM, Lanusse CE, Rodriguez JA: Enantioselective binding of albendazole sulphoxide to cytosolic proteins from helminth parasites. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):7-13. [PubMed:11980387 ]
  2. Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6. [PubMed:19846910 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Shewanella oneidensis (strain MR-1)
Pharmacological action
unknown
Actions
inhibitor
General Function:
Succinate dehydrogenase activity
Specific Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional (By similarity).
Gene Name:
Not Available
Uniprot ID:
P83223
Molecular Weight:
62447.475 Da
References
  1. Barrowman MM, Marriner SE, Bogan JA: The fumarate reductase system as a site of anthelmintic attack in Ascaris suum. Biosci Rep. 1984 Oct;4(10):879-83. [PubMed:6518278 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Merino G, Alvarez AI, Prieto JG, Kim RB: The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9. [PubMed:11901088 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23